Value
—- Trailing PER (last 12 months)
- —
- EPS zero or negative; no PER
- CautionEPS zero or negative
Not applicable
DMRA
Damora Therapeutics, Inc.
DMRA
Damora Therapeutics, Inc.
$ 18.4
-
Not applicable
Shown as separate facts (no combined rating)As of 2026-10-16
Insufficient data
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
| Asset | Price | Div. Yield |
|---|